TL1A Was Supposed to Be the Next Big Thing. Then Came the RA Data.

Why RA Is a Tougher Nut to Crack

The disappointing showing wasn't entirely shocking if you understand the underlying biology. TL1A is a signaling molecule that drives inflammation, particularly in the gut. In inflammatory bowel disease (IBD), TL1A appears to be a central villain: block it, and the inflammatory cascade calms down dramatically. Multiple companies have shown strong Phase 2 data in ulcerative colitis and Crohn's disease to prove it.

Rheumatoid arthritis is a different beast. The inflammation in RA joints is driven by a whole committee of troublemakers: TNF, IL-6, IL-17, B cells, macrophages, and specialized cells called fibroblast-like synoviocytes. Blocking TL1A is like firing one member of a ten-person wrecking crew. The damage might slow down, but it doesn't stop.

There's also a patient selection problem. IBD programs have increasingly focused on identifying "TL1A-high" patients who are most likely to respond. RA hasn't benefited from the same kind of biomarker-driven enrichment, so trials end up testing the drug in a more heterogeneous group where some patients' disease may not be TL1A-driven at all.

The Bigger Question: Is TL1A a One-Trick Pony?

This is where the story gets interesting for the broader field. Three of the world's biggest pharma companies have placed enormous bets on TL1A becoming a multi-indication blockbuster. The RA stumble forces an uncomfortable question: what if TL1A only works really well in the gut?

Merck has been the most aggressive in testing its TL1A antibody, tulisokibart, across indications beyond IBD. The company has Phase 2b trials running in RA, radiographic axial spondyloarthritis, and hidradenitis suppurativa. Roche has explored atopic dermatitis and MASH (the liver disease formerly known as NASH). These programs will now face heightened scrutiny.

To be fair, Spyre's data doesn't kill the TL1A thesis. It narrows it. The IBD data across multiple programs remain strong, and Phase 3 trials in ulcerative colitis and Crohn's disease are ongoing. If those deliver, TL1A antibodies are still on track to become a major drug class.

But the dream of TL1A as a universal anti-inflammatory skeleton key? That just got harder to sell.

What Happens to Spyre Now?

Spyre isn't abandoning TL1A entirely. The company is deprioritizing RA monotherapy, not torching its entire pipeline. Its lead program, SPY002, is still in a Phase 2 trial for ulcerative colitis (called SKYLINE), and the SKYWAY basket trial still has readouts coming for psoriatic arthritis and axial spondyloarthritis in Q4 2026. Those results will be critical in determining whether TL1A has legs outside the gut, or whether IBD is the ceiling.

The company also left a door open for combination therapy in RA. If TL1A blockade provides proof of mechanism but not enough firepower on its own, pairing it with another drug could theoretically boost the effect. That's a much longer, more expensive development path, though, and investors tend to get impatient with "maybe it works if we add something else."

The Takeaway for the TL1A Gold Rush

The TL1A story isn't over. It's just getting a reality check. For two years, the excitement around this target has been almost gravitational; every major pharma company wanted in, and valuations reflected a world where TL1A could treat a dozen diseases.

Spyre's RA data are a reminder that biology doesn't care about investor enthusiasm. Some targets work beautifully in one tissue and struggle in another. TL1A may well become a blockbuster drug class, but its home turf is looking more and more like the gut, not the joints.

The real test comes next. Merck's RA data for tulisokibart will either confirm that TL1A underwhelms in arthritis or suggest that Spyre's specific molecule was the issue. And the Phase 3 IBD readouts across multiple companies will determine whether the billions spent on this target were visionary or just very expensive FOMO.

For now, the TL1A hype train hasn't derailed. It's just been rerouted.

The Biotech Investor That Got Caught Peeking at the Answer Key

A federal court found RA Capital and Avilar Therapeutics guilty of willfully stealing a trade secret from Yale, awarding $4 million to Biohaven and the university. The verdict could reshape how biotech investors handle confidential academic science forever.